BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 26063224)

  • 1. Preclinical Development of Inactivated Rabies Virus-Based Polyvalent Vaccine Against Rabies and Filoviruses.
    Willet M; Kurup D; Papaneri A; Wirblich C; Hooper JW; Kwilas SA; Keshwara R; Hudacek A; Beilfuss S; Rudolph G; Pommerening E; Vos A; Neubert A; Jahrling P; Blaney JE; Johnson RF; Schnell MJ
    J Infect Dis; 2015 Oct; 212 Suppl 2(Suppl 2):S414-24. PubMed ID: 26063224
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant Protein Filovirus Vaccines Protect Cynomolgus Macaques From Ebola, Sudan, and Marburg Viruses.
    Lehrer AT; Chuang E; Namekar M; Williams CA; Wong TAS; Lieberman MM; Granados A; Misamore J; Yalley-Ogunro J; Andersen H; Geisbert JB; Agans KN; Cross RW; Geisbert TW
    Front Immunol; 2021; 12():703986. PubMed ID: 34484200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.
    Keshwara R; Hagen KR; Abreu-Mota T; Papaneri AB; Liu D; Wirblich C; Johnson RF; Schnell MJ
    J Virol; 2019 Mar; 93(6):. PubMed ID: 30567978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody quality and protection from lethal Ebola virus challenge in nonhuman primates immunized with rabies virus based bivalent vaccine.
    Blaney JE; Marzi A; Willet M; Papaneri AB; Wirblich C; Feldmann F; Holbrook M; Jahrling P; Feldmann H; Schnell MJ
    PLoS Pathog; 2013; 9(5):e1003389. PubMed ID: 23737747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
    Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
    J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetically modified rabies virus-vectored Ebola virus disease vaccines are safe and induce efficacious immune responses in mice and dogs.
    Shuai L; Wang X; Wen Z; Ge J; Wang J; Zhao D; Bu Z
    Antiviral Res; 2017 Oct; 146():36-44. PubMed ID: 28822816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Inactivated Rabies Virus-Based Ebola Vaccine, FILORAB1, Adjuvanted With Glucopyranosyl Lipid A in Stable Emulsion Confers Complete Protection in Nonhuman Primate Challenge Models.
    Johnson RF; Kurup D; Hagen KR; Fisher C; Keshwara R; Papaneri A; Perry DL; Cooper K; Jahrling PB; Wang JT; Ter Meulen J; Wirblich C; Schnell MJ
    J Infect Dis; 2016 Oct; 214(suppl 3):S342-S354. PubMed ID: 27456709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates.
    Callendret B; Vellinga J; Wunderlich K; Rodriguez A; Steigerwald R; Dirmeier U; Cheminay C; Volkmann A; Brasel T; Carrion R; Giavedoni LD; Patterson JL; Mire CE; Geisbert TW; Hooper JW; Weijtens M; Hartkoorn-Pasma J; Custers J; Grazia Pau M; Schuitemaker H; Zahn R
    PLoS One; 2018; 13(2):e0192312. PubMed ID: 29462200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Single-Dose Trivalent VesiculoVax Vaccine Protects Macaques from Lethal Ebolavirus and Marburgvirus Challenge.
    Matassov D; Mire CE; Latham T; Geisbert JB; Xu R; Ota-Setlik A; Agans KN; Kobs DJ; Wendling MQS; Burnaugh A; Rudge TL; Sabourin CL; Egan MA; Clarke DK; Geisbert TW; Eldridge JH
    J Virol; 2018 Feb; 92(3):. PubMed ID: 29142131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated or live-attenuated bivalent vaccines that confer protection against rabies and Ebola viruses.
    Blaney JE; Wirblich C; Papaneri AB; Johnson RF; Myers CJ; Juelich TL; Holbrook MR; Freiberg AN; Bernbaum JG; Jahrling PB; Paragas J; Schnell MJ
    J Virol; 2011 Oct; 85(20):10605-16. PubMed ID: 21849459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Further characterization of the immune response in mice to inactivated and live rabies vaccines expressing Ebola virus glycoprotein.
    Papaneri AB; Wirblich C; Cooper K; Jahrling PB; Schnell MJ; Blaney JE
    Vaccine; 2012 Sep; 30(43):6136-41. PubMed ID: 22884661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macaque Monoclonal Antibodies Targeting Novel Conserved Epitopes within Filovirus Glycoprotein.
    Keck ZY; Enterlein SG; Howell KA; Vu H; Shulenin S; Warfield KL; Froude JW; Araghi N; Douglas R; Biggins J; Lear-Rooney CM; Wirchnianski AS; Lau P; Wang Y; Herbert AS; Dye JM; Glass PJ; Holtsberg FW; Foung SK; Aman MJ
    J Virol; 2016 Jan; 90(1):279-91. PubMed ID: 26468532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.
    Singh K; Marasini B; Chen X; Ding L; Wang JJ; Xiao P; Villinger F; Spearman P
    J Virol; 2020 Apr; 94(9):. PubMed ID: 32075939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity of replication-deficient vesicular stomatitis virus based rabies vaccine in mice.
    Park JE; Shin HJ
    Vet Q; 2021 Dec; 41(1):202-209. PubMed ID: 33985418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.
    Warfield KL; Dye JM; Wells JB; Unfer RC; Holtsberg FW; Shulenin S; Vu H; Swenson DL; Bavari S; Aman MJ
    PLoS One; 2015; 10(3):e0118881. PubMed ID: 25793502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-in-human study to evaluate safety, tolerability, and immunogenicity of heterologous regimens using the multivalent filovirus vaccines Ad26.Filo and MVA-BN-Filo administered in different sequences and schedules: A randomized, controlled study.
    Bockstal V; Shukarev G; McLean C; Goldstein N; Bart S; Gaddah A; Anumenden D; Stoop JN; Marit de Groot A; Pau MG; Hendriks J; De Rosa SC; Cohen KW; McElrath MJ; Callendret B; Luhn K; Douoguih M; Robinson C
    PLoS One; 2022; 17(10):e0274906. PubMed ID: 36197845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-injection vaccine protects nonhuman primates against infection with marburg virus and three species of ebola virus.
    Geisbert TW; Geisbert JB; Leung A; Daddario-DiCaprio KM; Hensley LE; Grolla A; Feldmann H
    J Virol; 2009 Jul; 83(14):7296-304. PubMed ID: 19386702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Venezuelan equine encephalitis virus replicon particle vaccine protects nonhuman primates from intramuscular and aerosol challenge with ebolavirus.
    Herbert AS; Kuehne AI; Barth JF; Ortiz RA; Nichols DK; Zak SE; Stonier SW; Muhammad MA; Bakken RR; Prugar LI; Olinger GG; Groebner JL; Lee JS; Pratt WD; Custer M; Kamrud KI; Smith JF; Hart MK; Dye JM
    J Virol; 2013 May; 87(9):4952-64. PubMed ID: 23408633
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human Polyclonal Antibodies Produced through DNA Vaccination of Transchromosomal Cattle Provide Mice with Post-Exposure Protection against Lethal Zaire and Sudan Ebolaviruses.
    Bounds CE; Kwilas SA; Kuehne AI; Brannan JM; Bakken RR; Dye JM; Hooper JW; Dupuy LC; Ellefsen B; Hannaman D; Wu H; Jiao JA; Sullivan EJ; Schmaljohn CS
    PLoS One; 2015; 10(9):e0137786. PubMed ID: 26422247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
    Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
    PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.